Management of osteoporosis in the aging male: focus on zoledronic acid.

Paul K. Piper, Ugis Gruntmanis

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Osteoporosis in the aging male remains an important yet under-recognized and undertreated disease. Current US estimates indicate that over 14 million men have osteoporosis or low bone mass, and men suffer approximately 500,000 osteoporotic fractures each year. Men experience fewer osteoporotic fractures than women but have higher mortality after fracture. Bisphosphonates are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo markers of bone turnover, increase bone mineral density, decrease fractures, and improve survival in men with osteoporosis. Intravenous zoledronic acid may be a preferable alternative to oral bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, or significant gastrointestinal pathology. Zoledronic acid (Reclast) is approved in the US as an annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid (Zometa) 4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen deprivation therapy.

Original languageEnglish (US)
Pages (from-to)289-303
Number of pages15
JournalClinical interventions in aging
StatePublished - 2009

ASJC Scopus subject areas

  • Geriatrics and Gerontology


Dive into the research topics of 'Management of osteoporosis in the aging male: focus on zoledronic acid.'. Together they form a unique fingerprint.

Cite this